公开(公告)号：US20240067668A1

公开(公告)日：2024-02-29

申请号：US18259696

申请日：2021-12-29

申请人： VORONOI INC. ,  B2SBIO INC.

发明人： Yi Kyung Ko ,  Ah Reum Han ,  Jin Hee Park ,  Yeong Deok Lee ,  Hye Rim Im ,  Kyun Eun Kim ,  Dong Keun Hwang ,  Su Been Nam ,  Myung Hoe Heo ,  Se Rin Cho ,  Eun Hwa Ko ,  Sung Hwan Kim ,  Hwan Geun Choi

IPC分类号： C07F9/53 ,  A61P35/00

CPC分类号： C07F9/5325 ,  A61P35/00

摘要： The present invention relates to a heteroaryl derivative compound and a use thereof. Since the heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, the heteroaryl derivative can be usefully used as a therapeutic agent for EGFR-associated diseases.

公开(公告)号：US20230322753A1

公开(公告)日：2023-10-12

申请号：US18026793

申请日：2021-09-18

申请人： VORONOI INC. ,  VORONOIBIO INC. ,  B2SBIO INC.

发明人： Younho LEE ,  Juhee KANG ,  Yikyung KO ,  Jung Beom SON ,  Eunhwa KO ,  Sung Hwan KIM ,  Nam Doo KIM ,  Hwan Geun CHOI

IPC分类号： C07D413/14 ,  C07D413/04 ,  C07D498/08 ,  A61P35/00

CPC分类号： C07D413/14 ,  C07D413/04 ,  C07D498/08 ,  A61P35/00

摘要： The present invention relates to a pharmaceutical composition comprising a compound of the present invention, an isomer thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of cancer. The compound exhibits high inhibitory activity against epidermal growth factor receptor (EGFR) mutants or at least one of the wild-type or mutant ErbB2 and ErbB4 and as such, can be advantageously used for treatment of the cancer expressing same.